
Isomorphic Laboratories applies advanced AI to accelerate and improve drug discovery, enabling researchers to design molecules and predict their performance earlier in development. The company builds on AlphaFold and deep learning models to model biological systems, generate candidate therapeutics, and simulate compound behavior. It operates as an AI-first drug discovery platform focused on strategic research collaborations with pharmaceutical companies, biotech firms, and CROs. Core technologies include machine learning, deep learning, and AlphaFold-derived protein-structure modeling. Isomorphic targets the biopharma market to shorten discovery timelines and increase predictive accuracy for therapeutic development.

Isomorphic Laboratories applies advanced AI to accelerate and improve drug discovery, enabling researchers to design molecules and predict their performance earlier in development. The company builds on AlphaFold and deep learning models to model biological systems, generate candidate therapeutics, and simulate compound behavior. It operates as an AI-first drug discovery platform focused on strategic research collaborations with pharmaceutical companies, biotech firms, and CROs. Core technologies include machine learning, deep learning, and AlphaFold-derived protein-structure modeling. Isomorphic targets the biopharma market to shorten discovery timelines and increase predictive accuracy for therapeutic development.
Founded: 2021 (DeepMind/Alphabet spinout)
Headquarters: London
Core focus: AI-driven drug discovery using AlphaFold-derived protein modeling
Notable partnerships: Eli Lilly, Novartis, Johnson & Johnson
Major external funding: $600M led by Thrive Capital (Mar 31, 2025)
Early-stage therapeutic discovery and candidate design/prioritization
2021
Biotechnology Research
600000000
Participation from GV and follow-on capital from Alphabet
“Led by Thrive Capital with participation from GV and follow-on capital from Alphabet”
| Company |
|---|